Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

類似資料

• Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
  著者:: Paula Zapata-Cobo, 等
  出版事項: (2023-08-01)
• Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
  著者:: Sara Salvador-Martín, 等
  出版事項: (2021-01-01)
• Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
  著者:: Tatyana Valentinovna Mezenova, 等
  出版事項: (2012-04-01)
• Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
  著者:: Yoon Suk Jung, 等
  出版事項: (2021-01-01)
• Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis
  著者:: Mario Gaio, 等
  出版事項: (2024-07-01)